Loading
Life sciences · Journal article
Frontiers in Oncology · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Targeted alpha therapy (TAT) delivers high-linear-energy-transfer radiation over a few cell diameters and is being explored for resistant and microscopic solid-tumor disease. This targeted narrative review evaluates alpha-emitting platforms and clinical evidence by tumor type and development stage, with a focused literature update through 12 October 2026. Unlike broader radiochemistry-centered reviews, we place approved, randomized, early-phase, observational, and preclinical findings in separate evidence tiers. Radium-223 dichloride has randomized survival evidence in symptomatic bone-metastatic castration-resistant prostate cancer, whereas molecularly targeted actinium-225, lead-212, astatine-211, and thorium-227 agents remain investigational in the indications discussed. Updated examples include the 2026 ACTION-1 actinium-225-DOTATATE dosimetry substudy, the 2026 first-in-human astatine-211-MABG study, 2025 lead-212-DOTAMTATE phase II disclosures, and a negative 2025 mesothelin-targeted thorium-227 study. Quantitative outcomes are reported with their study design and limitations rather than interpreted as indirect head-to-head comparisons. Major barriers include isotope supply, incomplete daughter retention, salivary, marrow, and kidney toxicity, spatially heterogeneous target uptake, and uncertainty in patient-specific microdosimetry. We propose practical, imaging-led selection and a priority-ranked translational roadmap.